leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PHARMA REPORT

rss_Pharma.jpg...see all
Global Vaccines Market 2010-2025

Global Vaccines Market 2010-2025

  • Publication date: 16/03/2010
  • Number of Pages: 206
  1. Report Details
  2. Table of Contents
  3. Companies Listed

Report Details

– clinical needs driving technological progress and commercial growth

In 2009, the global market for vaccines achieved sales of over $10bn. Hundreds of millions of people are affected by infectious diseases that can be fought by vaccination. Despite controversy, vaccine use remains one of the greatest successes in the fight against disease - one with a long history. This market will achieve sustained growth over the next 15 years, our new study reveals. Increasingly, governments recognise the benefits of mass vaccination, with successive vaccines delivering healthcare solutions on a large scale, a trend set to continue.

Global Vaccines Market 2010-2025
provides a detailed analysis of the human vaccines market, predicting how and why it will expand in coming years. Our study provides a detailed forecast of the existing market, dividing it into major groups, from paediatric vaccines to prophylactic cancer treatments. Our report shows the commercial potential of vaccine classes from 2010 to 2025. We examine the most-successful current vaccines in particular, forecasting their sales and discussing their prospects in detail.

Which vaccines will achieve blockbuster sales from 2010 onwards? Which classes will experience the fastest growth, and what will cause this market expansion? What are the greatest unmet needs in vaccine use? What are the principal market drivers and restraints? What conditions are most likely to benefit from vaccine solutions in future, especially disorders currently un-served or under-served by treatments? This report covers those and other crucial questions, providing the information that you need. Our new study examines the biotechnological possibilities, determining which companies and which products are best placed to succeed in the vaccines market.

Comprehensive analysis of the global vaccines market

Global Vaccines Market 2010-2025 examines that sector through a comprehensive review of information sources. We harness both primary and secondary research. This report provides unique sales forecasts, market share analyses, discussions of R&D pipeline developments and analyses of commercial drivers and restraints, including a SWOT analysis. There are 75 tables and figures included, as well as three original interviews with relevant experts. The result is a comprehensive market- and industry-centred study, with detailed analyses and informed opinion to benefit your work.

Why you should buy Global Vaccines Market 2010-2025

This report gives you the following benefits in particular:
• You will receive a comprehensive analysis of the prospects for vaccines from 2010 to 2025, including predicted revenues, growth rates and other data for leading products
• You will receive an overall forecast for the global vaccines market from 2010 to 2025, as well as those for main classes, with comprehensive discussions and other supporting information
• You will find out where the market is heading – both technologically and commercially – from 2010 onwards
• You will discover the prospects for leading companies from 2010 onwards
• You will identify key R&D pipeline developments and up-and-coming products
• You will analyse the drivers, restraints, competition and opportunities influencing the vaccines sector
• You will investigate under-met needs in that sector, with both therapeutic requirements and commercial opportunities discussed
• You will discover expert views from our survey, including full interview transcripts.

You can obtain this report today

Nobody with an interest in the vaccines sector should overlook this new study. We predict that total revenues will increase. Recent technological advances have led to high expectations for vaccines currently in development. With rising demand worldwide and currently-unmet needs, this market holds significant potential for technological innovation and revenue growth. Do you want to harness those opportunities? You can stay ahead by ordering this report today.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

 

Table of Contents

1. Executive Summary
1.1 Vaccines Market Review
1.2 Overview of Report Content and Methods Used

2. Vaccines and Vaccine-Preventable Diseases
2.1 Immunisation and Types of Vaccine
2.1.1 Vaccines: a Healthcare Triumph
2.1.2 The Immune System and Natural Immunity
2.1.3 Edward Jenner Laid the Foundation for Modern Vaccines
2.1.4 Vaccines Work by Creating Artificial Immunity
2.1.5 Vaccine Formulation
2.1.6 Types of Vaccine
2.1.7 Live Attenuated Vaccines
2.1.8 Recombinant Live Vaccines
2.1.9 Inactivated Vaccines
2.1.10 Toxoid Vaccines
2.1.11 Conjugate Vaccines
2.1.12 Recombinant Subunit Vaccines
2.1.13 DNA Vaccines
2.1.14 Recombinant Vector Vaccines
2.2 Vaccine-Preventable Diseases
2.2.1 Chickenpox and Shingles
2.2.2 Cholera
2.2.3 Diphtheria
2.2.4 Haemophilus Influenzae Type b (Hib) Diseases
2.2.5 Hepatitis A
2.2.6 Hepatitis B
2.2.7 Human Papillomavirus (HPV) - Cervical Cancer
2.2.8 Influenza
2.2.9 Seasonal Influenza
2.2.10 Pandemic Influenza
2.2.11 Influenza Vaccination
2.2.12 Japanese Encephalitis
2.2.13 Measles
2.2.14 Neisseria Meningitidis - Meningococcal Diseases
2.2.15 Mumps
2.2.16 Pertussis
2.2.17 Polio
2.2.18 Rabies
2.2.19 Rotavirus Infections
2.2.20 Rubella
2.2.21 Streptococcus Pneumoniae Infections
2.2.22 Tetanus
2.2.23 Tick-Borne Encephalitis
2.2.24 Tuberculosis
2.2.25 Typhoid
2.2.26 Yellow Fever

3. The Global Vaccines Market, 2010-2025
3.1 Global Vaccines Market, 2009
3.1.1 Vaccine Types
3.1.2 Leading Vaccine Types
3.1.3 Leading Vaccine Brands
3.1.4 Leading Vaccine Manufacturers
3.2 Global Vaccine Market Forecast, 2010-2025
3.2.1 Total Market Tables and Figures
3.2.2 The Market by Subdivisions: Tables and Figures
3.2.3 World Vaccine Market Growth
3.2.4 The World Vaccine Market: Fastest- and Slowest-Growing Categories
3.3 Paediatric Vaccines
3.3.1 Leading Paediatric Vaccine Brands, 2009
3.3.2 Leading Paediatric Vaccine Manufacturers, 2009
3.3.3 Paediatric Vaccine Market Share will Slide?
3.3.4 Varivax (Merck & Co/Sanofi Pasteur MSD)
3.3.5 M-M-R II (Merck & Co/Sanofi Pasteur)
3.3.6 ProQuad (Merck & Co)
3.3.7 Varivax/M-M-R-II/ProQuad Sales Analysis, 2009
3.3.8 Varivax/M-M-R-II/ProQuad Sales Forecast, 2010-2015
3.3.9 Prevnar/Prevenar (Wyeth)
3.3.10 Prevnar/Prevenar Revenues, 2009
3.3.11 Prevnar/Prevenar/Prevnar Sales Forecast, 2010-2015
3.3.12 Polio/Pertussis/Hib Vaccines (Sanofi-Aventis)
3.3.13 Polio/Pertussis/Hib Vaccines (Sanofi- Aventis) Sales Forecast, 2010-2015
3.3.14 Infanrix/Pediarix (GlaxoSmithKline)
3.3.15 Infanrix/Pediarix Sales Forecast, 2010-2015
3.3.16 RotaTeq (Merck & Co/Sanofi Pasteur MSD)
3.3.17 RotaTeq Sales Forecast, 2010-2015
3.3.18 Rotarix (GSK)
3.3.19 Rotarix Sales Forecast, 2010-2015
3.4 Influenza Vaccines
3.4.1 Influenza Market Forecast 2010-2025
3.4.2 Influenza Market Forecast by Brand, 2010-2015
3.4.3 Influenza Vaccines Growth Driven by Pandemic Influence
3.4.4 Fluzone/Vaxigrip/Mutagrip (Sanofi-Aventis/Sanofi Pasteur MSD)
3.4.5 New Fluzone Formula for Elderly
3.4.6 Fluarix and FluLaval (GlaxoSmithKline)
3.5 Adult/Other Vaccines
3.5.1 Leading Adult/Other Vaccine Brands, 2009
3.5.2 Leading Adult/Other Vaccine Manufacturers, 2009
3.5.3 Adult/Other Vaccine Market Forecast, 2010-2025
3.5.4 Zostavax (Merck & Co/Sanofi Pasteur MSD)
3.5.5 Zostavax Sales Forecast, 2010-2015: a New Blockbuster?
3.5.6 Pneumovax (Merck & Co/Sanofi Pasteur MSD)
3.5.7 Pneumovax Sales Forecast, 2010-2015
3.5.8 Adacel (Sanofi-Aventis/Sanofi Pasteur MSD)
3.5.9 Adacel Market Forecast, 2010-2015
3.6 Prophylactic Cancer Vaccines
3.6.1 Leading Prophylactic Cancer Brands, 2009
3.6.2 Leading Prophylactic Cancer Vaccine Manufacturers, 2009
3.6.3 Prophylactic Cancer Vaccine Market Forecast, 2010-2025
3.6.4 Gardasil (Merck & Co./Sanofi Pasteur MSD/CSL)
3.6.5.Expanded Indications for Gardasil
3.6.6 Gardasil Sales Forecast 2010-2015
3.6.7 Cervarix (GlaxoSmithKline)
3.6.8 New Vaccine Blockbuster: Cervarix Sales Forecast, 2010-2015
3.7 Hepatitis Vaccines
3.7.1 Leading Hepatitis Vaccine Manufacturers, 2009
3.7.2 Hepatitis Vaccine Market Forecast, 2010-2025
3.7.3 GSK Hepatitis Vaccines
3.7.4 Havrix
3.7.5 Engerix-B
3.7.6 Twinrix/Ambirix
3.7.7 Merck & Co./Sanofi Pasteur MSD Hepatitis Vaccines
3.7.8 Vaqta/Avaxim
3.7.9 Recombivax HB/HBvaxPRO
3.7.10 Leading Hepatitis Vaccine Brand Forecasts, 2010-2025
3.8 Therapeutic Vaccines, 2010-2025
3.8.1 Rapid Growth for Therapeutic Vaccines
3.8.2 Most Therapeutic Vaccines are Not Registered Drugs
3.8.3 Grazax (ALK-Abelló)

4. Factors Influencing the Global Vaccines Industry and Market
4.1 SWOT Analysis of the Vaccines Market in 2010
4.2 Key Strengths of the Vaccines Sector
4.2.1 Vaccines are Important Agents with High Efficacy
4.2.2 New Vaccine Technologies
4.2.2.1 Vaccine Manufacturers are Expanding the Scope of Vaccines
4.2.2.2 New Types of Vaccine
4.2.2.3 New Adjuvants for Vaccines
4.2.2.4 New Vaccine Delivery Mechanisms and Formulations
4.2.2.5 Other Developments in Vaccine Technology
4.2.3 New High-Margin Vaccines
4.2.4 Vaccines Will Not Face Significant Generic Competition
4.2.5 Personalised Vaccines
4.3 The Vaccines Industry: Weaknesses
4.3.1 Vaccine Research and Development is Lengthy and Expensive
4.3.1.1 The Vaccine Research and Development Process
4.3.1.2 Vaccine Research and Development will be Outsourced to Emerging Markets
4.3.2 Vaccine Manufacturing
4.3.2.1 Vaccine Manufacturing has High Costs
4.3.2.2 China, India and Brazil Will Become Hubs for Manufacturing Paediatric Vaccines
4.3.3 Consolidation Among Vaccine Manufacturers
4.4 Opportunities for the Vaccines Sector
4.4.1 Vaccines for Diseases Currently Without a Vaccine
4.4.1.1 The Most Important Non-Vaccine-Preventable Diseases
4.4.1.2 Cancer
4.4.1.3 Dengue Fever
4.4.1.4 Enterohaemorrhagic Escherichia Coli (EHEC)
4.4.1.5 Epstein-Barr Virus (EBV)
4.4.1.6 Helicobacter Pylori Infections
4.4.1.7 Hepatitis C
4.4.1.8 Hepatitis E
4.4.1.9 HIV/AIDS
4.4.1.10 Malaria
4.4.1.11 Nosocomial Infections
4.4.1.12 Clostridium Difficile
4.4.1.13 Staphylococcus Spp. Bacteria
4.4.1.14 Other Nosocomial Infections
4.4.1.15 Respiratory Infections
4.4.1.16 Roundworm and Hookworm Infections
4.4.1.17 Sexually-Transmitted Diseases
4.4.1.18 Chlamydia
4.4.1.19 Herpes Virus Simplex Virus
4.4.1.20 Other Sexually-Transmitted Diseases
4.4.1.21 Tobacco
4.4.1.22 West Nile Virus Infections
4.4.2 Improved Vaccines for Partially Vaccine-Preventable Diseases
4.4.2.1 Vaccines Effective Against More Strains
4.4.2.2 Towards a Universal Influenza Vaccine
4.4.2.3 The Need for an Improved Tuberculosis Vaccines
4.4.3 Biodefence
4.4.4 The Future for Bioterrorism Vaccines
4.4.5 Pandemic-Preparedness
4.4.6 Changing World Demographics
4.4.6.1 Population Increase
4.4.6.2 Emerging-Market Economies
4.5 Threats Facing the Vaccines Sector
4.5.1 The Anti-Vaccine Movement
4.5.1.1 Misinformation about Side-Effects of Vaccines
4.5.1.2 MMR in the UK
4.5.1.3 Controversy Surrounding Mercury-Containing Vaccines
4.5.1.4 Campaigns Against Cervical Cancer Vaccines
4.5.1.5 Consequences of Anti-Vaccine Campaigns
4.5.2 Vaccines in the Developing World
4.5.2.1 Vaccine Distribution Networks
4.5.2.2 Vaccine Costs in Developing Countries
4.5.2.3 Improving Access to Vaccines in the Developing World

5. The Vaccines R&D Pipeline
5.1 The Most-Promising Sectors of the Vaccines R&D Pipeline
5.2 Paediatric Vaccines Pipeline
5.2.1 Paediatric Pipeline Vaccines Will Address Key Unmet Needs, 2010-2015
5.2.2 Synflorix (GlaxoSmithKline)
5.2.3 Prevnar 13 (Wyeth)
5.2.4 Menactra Toddler (Sanofi-Aventis)
5.2.5 Menveo (Novartis)
5.2.6 MenACWY-TT (GlaxoSmithKline)
5.2.7 Menhibrix (GlaxoSmithKline)
5.2.8 Hexaxim & Unifive (Sanofi-Aventis)
5.2.9 MenB (Novartis)
5.2.10 Meningitis B Vaccine (Wyeth)
5.2.11 ORV 116E (Bharat Biotech)
5.2.12 Streptococcus Pneumoniae Vaccine (Intercell)
5.3 Influenza Vaccines Pipeline
5.3.1 Key Developments in Influenza Vaccines, 2010-2015
5.3.2 Cell Culture Influenza Vaccines
5.3.2.1 The Switch from Eggs
5.3.2.2 Optaflu (Novartis)
5.3.2.3 FluBlok (Protein Sciences/UMN Pharma)
5.3.2.4 Influvac TC (Solvay)
5.3.2.5 Vero-Cell Technology (Baxter/DynPort)
5.3.2.6 Per.C6 (Sanofi-Aventis/Crucell/Lonza)
5.3.2.7 VLP Vaccines (Novavax)
5.3.3 Pipeline Pandemic H5N1 (Avian) Influenza Vaccines
5.3.3.1 Pandemic and Pre-Pandemic H5N1 Vaccines
5.3.3.2 Celvapan (Baxter)
5.3.3.3 Panvax (CSL)
5.3.3.4 GlaxoSmithKline's H5N1 Vaccines
5.3.3.5 Novartis' Pre-Pandemic Vaccines
5.3.3.6 Pandemic H5N1 VLP Influenza Vaccine (Novavax)
5.3.3.7 Sanofi-Aventis' H5N1 Influenza Vaccine Programme
5.3.3.8 Panflu (H5N1 Vaccine, Sinovac)
5.3.4 Pipeline Pandemic Novel H1N1 (Swine Flu) Influenza Vaccines
5.3.4.1 GlaxoSmithKline
5.3.4.2 Novartis
5.3.4.3 Novavax
5.3.4.4 Sanofi-Aventis
5.3.4.5 Sinovac
5.3.4.6 Vaxine
5.3.5 Novel Delivery Systems for Influenza Vaccines
5.3.6 New Adjuvants for Influenza Vaccines
5.3.6.1 Fluad (Novartis)
5.3.6.2 Grippol Neo (Solvay/Petrovax)
5.3.6.3 Iscomatrix Adjuvant (CSL)
5.3.6.4 Pandemic Influenza Vaccine Enhancement Patch (Intercell)
5.3.6.5 Advax (Vaxine)
5.3.6.6 Vaxfectin (Vical)
5.3.6.7 VaxiSome (NasVax)
5.3.7 Potential Universal Influenza Vaccine
5.3.7.1 ACAM-Flu-A (Sanofi-Aventis)
5.3.7.2 Multimeric Universal Influenza Vaccine (Biondvax)
5.4 Other/Adult Vaccines Pipeline
5.4.1 Key Developments in Adult/Other Vaccines, 2010-2015
5.4.2 What are the Prospects for new Adult Vaccines from 2015 to 2025?
5.4.3 Ixiaro (Novartis/Intercell)
5.4.4 Imojev (Sanofi-Aventis)
5.4.5 Adenovirus Vaccines (Teva)
5.4.6 Flavinum (Crucell)
5.4.7 Expanded Indications for Adacel
5.4.8 Simplirix (GlaxoSmithKline)
5.4.9 ALVAC-HIV (Sanofi-Aventis)
5.4.10 Mosquirix (GlaxoSmithKline)
5.4.11 rPA 102 (Anthrax Vaccine, Emergent BioSolutions)
5.4.12 SparVax (PharmAthene)
5.4.13 rF1V Plague Vaccine (DynPort)
5.4.14 Imvamune (Bavarian Nordic)
5.4.15 ACE393/Campylobacter Jejuni Vaccine (ACE Biosciences/Biotecnol)
5.4.16 CholeraGarde (Celldex/Vaccine Technologies)
5.4.17 Cytomegalovirus Vaccine (Sanofi-Aventis)
5.4.18 Dengue Fever Vaccine (Sanofi-Aventis)
5.4.19 Dengue Virus Vaccine (GlaxoSmithKline)
5.4.20 Escherichia Coli Travellers' Diarrhoea Vaccine Patch (Intercell)
5.4.21 tgAAC09 (Targeted Genetics)
5.4.22 VRC-HIVADV014-00VP (GenVec/NIAID Vaccine Research Center)
5.4.23 ACAM-Cdiff (Sanofi-Aventis)
5.4.24 Pseudomonas Aeruginosa Vaccines, (Intercell and Novartis)
5.4.25 V 710 (Staphylococcus Aureus Vaccine (Merck & Co./Intercell)
5.4.26 PentaStaph (Nabi Biopharmaceuticals/GlaxoSmithKline)
5.4.27 Herpes Zoster Vaccine (GlaxoSmithKline)
5.4.28 GSK M72/Tuberculosis Vaccine (GlaxoSmithKline)
5.4.29 MVA85A/AERAS-485 (Tuberculosis Vaccine, Emergent BioSolutions)
5.4.30 Ty800 (Oral Typhoid Vaccine, Celldex)
5.4.31 Typhoid Vaccine (Emergent Biosolutions)
5.4.32 West Nile Vaccine (Sanofi-Aventis)
5.5 Hepatitis Vaccines Pipeline
5.5.1 Heplisav (Dynavax)
5.5.2 V419 (Paediatric Hepatitis B Vaccine (Merck & Co)
5.5.3 Prophylactic Hepatitis B Vaccine (Vaxine)
5.5.4 Hepatitis E Vaccine (GlaxoSmithKline)
5.6 Prophylactic Cancer Vaccines Pipeline
5.6.1 V503 (Nine-Valent Human Papillomavirus Vaccine, Merck & Co.)
5.6.2 Epstein-Barr Virus Vaccine (AstraZeneca)
5.6.3 Helicobacter Pylori Vaccine (Novartis)
5.7 Therapeutic Vaccines Pipeline
5.7.1 Therapeutic Vaccines for Cancer
5.7.1.1 Provenge/Sipuleucel-T (Dendreon)
5.7.1.2 BiovaxID (Accentia Biopharmaceuticals)
5.7.1.3 MVax (Avax Technologies)
5.7.1.4 MAGE-A3 ASCI (GlaxoSmithKline/Ludwig Institute of Cancer Research)
5.7.1.5 Stimuvax (Merck KGaA/Oncothyreon)
5.7.1.6 TroVax (Oxford BioMedica)
5.7.1.7 OncoVAX (Vaccinogen/Intracel)
5.7.1.8 Allovectin-7 (Vical/AnGes MG)
5.7.1.9 PF-4948568/CDX-110 (Pfizer/Celldex)
5.7.1.10 GV1001 (KAEL-GemVax)
5.7.2 Therapeutic Vaccines for Hepatitis
5.7.2.1 Therapeutic Hepatitis B Vaccine (Emergent Biosolutions)
5.7.2.2 GI-5005/Hepatitis C Treatment Vaccine (GlobeImmune)
5.7.2.3 Hepatitis C Vaccine (Intercell/Novartis)
5.7.3 Therapeutic Vaccines for HIV Infection
5.7.4 Therapeutic Vaccines for Other Viral Infections
5.7.4.1 TG 4001/R3484 (MVA-HPV-IL2/HPV Vaccine (Transgene/Roche)
5.7.4.2 Cytomegalovirus Therapeutic Vaccine (Vical)
5.7.5 Therapeutic Addiction Vaccines
5.7.5.1 Addiction Vaccines Will Target Nicotine and Drug Dependency
5.7.5.2 NicVAX (Nabi Biopharmaceuticals)
5.7.5.3 NIC002 (Novartis/Cytos Biotechnology)
5.7.5.4 TA-NIC (Celtic Pharma)
5.7.5.5 Niccine (Independent Pharmaceutica)
5.7.5.6 TA-CD (Celtic Pharma)
5.7.6 Therapeutic Allergy Vaccines
5.7.6.1 House Dust Mite Allergy Vaccine (ALK-Abelló/Schering-Plough)
5.7.7 Therapeutic Vaccines for Chronic Disease
5.7.7.1 Alzheimer's Disease

6. Interviews with Relevant Experts
6.1 Dr David S. Fedson, MD, Formerly Professor of Medicine, University of Virginia School of Medicine; Former Director of Medical Affairs, Aventis Pasteur MSD
6.2 Dr Raafat E. F. Fahim, Ph.D., President and Chief Executive Officer, Nabi Biopharmaceuticals
6.3 Dr Tamar Ben-Yedida, Director of R&D, Biondvax Pharmaceuticals

7. Conclusions of this Study
7.1 The Vaccines Market will Experience Strong Growth from 2010 to 2025
7.2 The Balance of Power within the Vaccines Market will Shift
7.3 Public Misunderstanding of the Dangers of Vaccination will Continue to Threaten Market Growth
7.4 Global Vaccines Market: Summary

List of Tables
Table 2.1 Vaccine-Preventable Disease Statistics
Table 2.2 Influenza Virus Types
Table 3.1 Definition of Vaccine Types Used in this Report
Table 3.2 Vaccine Sales by Type, 2009
Table 3.3 Vaccine Sales by Brand, 2009
Table 3.4 Vaccine Sales by Manufacturer, 2009
Table 3.5 Global Vaccine Market: Sales Forecast, 2010-2025
Table 3.6 Global Vaccine Market: Sales Forecast by Vaccine Type, 2010-2025
Table 3.7 Global Vaccine Market: Sales Forecast by Vaccine Type, 2015-2025
Table 3.8 Paediatric Vaccine Sales by Brand, 2009
Table 3.9 Paediatric Vaccine Sales by Manufacturer, 2009
Table 3.10 Paediatric Vaccine Market: Sales Forecast, 2010-2025
Table 3.11 Varivax/M-M-R-II/ProQuad: Sales Analysis, 2009
Table 3.12 Leading Paediatric Vaccines: Sales Forecasts, 2010-2015
Table 3.13 Example Brands for Polio/Pertussis/Hib Vaccines, 2009
Table 3.14 Brands in the Infanrix/Pediarix Range of Vaccines, 2009
Table 3.15 Influenza Vaccine Market: Sales Forecast, 2010-2025
Table 3.16 Leading Influenza Brands: Sales Forecasts, 2010-2025
Table 3.17 Adult/Other Vaccine Sales by Brand, 2009
Table 3.18 Adult/Other Vaccine Sales by Manufacturer, 2009
Table 3.19 Adult/Other Vaccines: Sales Forecast, 2010-2025
Table 3.20 Leading Adult/Other Vaccine Brands: Sales Forecasts, 2010-2015
Table 3.21 Prophylactic Cancer Vaccines: Sales by Manufacturer, 2009
Table 3.22 Prophylactic Cancer Vaccine Market: Sales Forecast, 2010-2025
Table 3.23 Prophylactic Cancer Vaccine Brands: Sales Forecasts, 2010-2025
Table 3.24 Hepatitis Vaccine Sales by Manufacturer, 2009
Table 3.25 Hepatitis Vaccine Market: Sales Forecast, 2010-2025
Table 3.26 Leading Hepatitis Vaccine Manufacturers: Sales Forecasts, 2010-2015
Table 3.27 Therapeutic Vaccines Market: Sales Forecast, 2010-2025
Table 4.1 SWOT Analysis for the Global Vaccines Market, 2010
Table 4.2 Selected Diseases Currently Without a Vaccine, 2010
Table 5.1 Key Pipeline Paediatric Vaccines, 2010
Table 5.2 Key Cell-Culture Influenza Vaccines, 2010
Table 5.3 Key Pandemic H5N1 (Avian) Influenza Vaccines, 2010
Table 5.4 Key Novel H1N1 Influenza (Swine Flu) Vaccines, 2010
Table 5.5 Key Pipeline Influenza Vaccines with Novel Delivery Systems, 2010
Table 5.6 Key Pipeline Influenza Vaccines with Novel Adjuvants, 2010
Table 5.7 Key Pipeline Other/Adult Vaccines: Phase III & Later, 2010
Table 5.8 Key Pipeline Other/Adult Vaccines: Phase II, 2010
Table 5.9 Key Pipeline Other/Adult Vaccines: Phase I, 2010
Table 5.10 Key Pipeline Hepatitis Vaccines, 2010
Table 5.11 Key Pipeline Prophylactic Cancer Vaccines, 2010
Table 5.12 Key Pipeline Therapeutic Cancer Vaccines, 2010
Table 5.13 Key Pipeline Therapeutic Hepatitis Vaccines, 2010
Table 5.14 Key Pipeline Therapeutic HIV/AIDS Vaccines, 2010
Table 5.15 Key Pipeline Therapeutic Addiction Vaccines, 2010
Table 5.16 Key Pipeline Therapeutic Chronic Disease Vaccines, 2010

List of Figures
Figure 3.1 Vaccine Sales by Type, 2009
Figure 3.2 Vaccine Sales by Brand, 2009
Figure 3.3 Vaccine Sales by Manufacturer, 2009
Figure 3.4 Global Vaccine Market: Sales Forecast 2010-2025
Figure 3.5 Global Vaccine Market: Sales Forecast by Vaccine Type, 2010-2025
Figure 3.6 Global Vaccine Market: Sales Shares by Vaccine Type, 2010-2025
Figure 3.7 Paediatric Vaccine Sales by Brand, 2009
Figure 3.8 Paediatric Vaccine Sales by Manufacturer, 2009
Figure 3.9 Paediatric Vaccine Market: Sales Forecast, 2010-2025
Figure 3.10 Varivax/M-M-R II/Proquad: Sales Forecast, 2010-2015
Figure 3.11 Prevenar/Prevnar/Prevnar 13: Sales Forecast, 2010-2015
Figure 3.12 Polio/Pertussis/Hib Vaccines (Sanofi-Aventis): Sales Forecast, 2010-2015
Figure 3.13 Infanrix/Pediarix Market: Sales Forecast, 2010-2015
Figure 3.14 Rotateq and Rotarix Market: Sales Forecast, 2010-2015
Figure 3.15 Influenza Vaccine Market: Sales Forecast, 2010-2025
Figure 3.16 Leading Influenza Vaccine Market: Sales Forecast, 2009-2015
Figure 3.17 Adult/Other Vaccine Sales by Manufacturer, 2009
Figure 3.18 Adult/Other Vaccines: Sales Forecast, 2009-2025
Figure 3.19 Zostavax Sales Forecast, 2009-2015
Figure 3.20 Pneumovax Sales Forecast, 2009-2015
Figure 3.21 Adacel Sales Forecast, 2009-2015
Figure 3.22 Prophylactic Cancer Vaccine Sales by Manufacturer, 2009
Figure 3.23 Prophylactic Cancer Vaccine Market: Sales Forecast, 2009-2025
Figure 3.24 Gardasil Sales Forecast, 2009-2015
Figure 3.25 Cervarix Sales Forecast, 2009-2015
Figure 3.26 Hepatitis Vaccine Market: Sales Forecast, 2009-2025
Figure 3.27 Hepatitis Vaccine Leading Brands: Sales Forecast, 2009-2015
Figure 3.28 Therapeutic Vaccine Market: Sales Forecast, 2009-2025 

Companies Listed

ALK-Abelló
Acambis
Accentia
ACE Biosciences
Advisory Committee on Immunization Practices (ACIP)
Aeras Global TB Vaccine Foundation
AFFiRiS
Aflunov
AlphaVax
Allergy Therapeutics
AnGes MG
Astellas
AstraZeneca
Avax Technologies
Australian Therapeutic Goods Administration (TGA)
Barr
Bavarian Nordic
Baxter International
BD, Bector, Dickinson & Co.
Bharat Biotech
Bill & Melinda Gates Foundation
BioDiem
Biogen Idec
Bioject
Biondvax Pharmaceuticals
Biotecnol
Cambridge Biostability
Centers for Disease Control (CDC)
Celldex
Celtic Pharma
China National Biotec Group
Chinese State Food and Drug Administration (SFDA)
Chiron
Crucell
CSL Limited
Cytos Biotechnology
Daiichi-Sankyo
Dendreon
Department of Health and Human Services (HHS)
Diamyd Medical
DynPort Vaccine Company
Dynavax
Elan
EMEA
Emergent BioSolutions
FDA (US)
Food and Drug Administration in Thailand (TFDA)
Genelabs
Genetic Immunity
GenVec
Geron
Green Cross
GlaxoSmithKline (GSK)
GlobeImmune
Independent Pharmaceutica
Inovio Biomedical
Intercell
International AIDS Vaccine Initiative (IAVI)
Johnson & Johnson
Karolinska Institutet
LigoCyte
LipoNova
Lonza
Ludwig Institute for Cancer Research
MedImmune
Menarini
Merck & Co
Merck KGaA
Mitsubishi Tanabe Pharma
Nabi Biopharmaceuticals
NasVax
National Institute of Allergy and Infectious Diseases (NIAID)
NIAI
NIAID Vaccine Research Center
Nobilon
Novartis
Novavax
Oncothyreon
Oxford BioMedica
PepTcell
Petrovax
Pfizer
PharmAthene
Pharmexa
Protein Sciences
Ranbaxy
Roche
Sanofi Aventis
Sanofi Pasteur MSD
Schering-Plough
Serum Institute of India
Sinovac
Solvay
Statens Serum Institute of Denmark (SSI)
Takeda
Targeted Genetics
Teva
Thai Ministry of Public Health
Transgene
Tripep
UMN Pharma
UNICEF
University of Queensland, Australia
University of Virginia School of Medicine
UK Defence Science and Technology Laboratory (Dstl)
US Army
US Department of Health and Human Services (HHS)
Vaccine Technologies
Vaccinogen
VaxGen
Vaxine
Vical
Virax
World Health Organisation (WHO)
Wistar Institute
Wyeth 

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close